biostudies-literatureSimbrunner BAustrian Science Fund FWFClinical Research Groups Programme of the Ludwig Boltzmann GesellschaftÖsterreichische Gesellschaft für Gastroenterologie und HepatologieMedical Scientific Fund of the Mayor of the City of Vienna648-661https://www.ebi.ac.uk/biostudies/studies/S-EPMC12904196biostudies-literatureUnknown63(5)<h4>Background</h4>Extracellular matrix (ECM) remodelling in advanced chronic liver disease (ACLD) is characterised by hepatic fibrosis and (sinusoidal) basement membrane development contributing to portal hypertension (PH) and clinical complications.<h4>Methods</h4>Patients with stable ACLD (n = 232) undergoing hepatic venous pressure gradient (HVPG) measurement were included. Blood biomarkers reflecting fibrosis formation (PRO-C3, PRO-C6, PRO-C4 and PRO-C18L) and degradation (C3M, C4M and C6Ma3), as well as the Enhanced Liver Fibrosis (ELF) score were measured. Associations with disease severity and liver-related events (LRE: decompensation, acute-on-chronic liver failure, or liver-related death) were analysed.<h4>Results</h4>The cohort included 131 (57%) patients with decompensated ACLDAlimentary pharmacology & therapeuticsBiomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease.PMC12904196J-4934Wissenschaftsfoerderung_2022LBG_KFG_22_3221047J‐4934Semmler GScheiner BBalcar LMarculescu RTrauner MAlmeida Calvao JMandorfer MLeeming DJSimbrunner BKramer GJachs MKarsdal MVillesen IFReiberger TMaurer JZinober KHartl LHofer BSfalseBiomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease.<h4>Background</h4>Extracellular matrix (ECM) remodelling in advanced chronic liver disease (ACLD) is characterised by hepatic fibrosis and (sinusoidal) basement membrane development contributing to portal hypertension (PH) and clinical complications.<h4>Methods</h4>Patients with stable ACLD (n = 232) undergoing hepatic venous pressure gradient (HVPG) measurement were included. Blood biomarkers reflecting fibrosis formation (PRO-C3, PRO-C6, PRO-C4 and PRO-C18L) and degradation (C3M, C4M and C6Ma3), as well as the Enhanced Liver Fibrosis (ELF) score were measured. Associations with disease severity and liver-related events (LRE: decompensation, acute-on-chronic liver failure, or liver-related death) were analysed.<h4>Results</h4>The cohort included 131 (57%) patients with decompensated ACLD2026-01-01T00:00:00Z2026 Mar2026-07-15T18:01:57.218Z2026-07-08T03:08:27.231ZS-EPMC129041964107788610.1111/apt.70407